Navigation Links
Adlyfe Appoints Roxanne Duan as Vice President of Research
Date:9/17/2007

ROCKVILLE, Md., Sept. 17 /PRNewswire/ -- Adlyfe, a private company developing novel diagnostic testing technologies for early targets of amyloid diseases, announced today that it has appointed Roxanne Duan, Ph.D. as Vice President of Research. Dr. Duan will be responsible for overseeing the Adlyfe's Research efforts and will report directly to the Chief Executive Officer.

Duan comes to Adlyfe with nearly two decades of experience. Most recently, Dr. Duan served as Vice President of Research at Functional Genetics, Inc., where she made major impact on developing antibody therapeutics for infectious diseases and improving a gene perturbation technology that facilitated drug target discovery and validation. Prior to Functional Genetics, Dr. Duan was the project leader and co-inventor of several clinical protein therapeutic candidates at Human Genome Sciences (HGS), covering areas of cardiovascular diseases, wound repair, and diabetes. In addition, she holds more than 20 issued patents in the area of protein therapeutics and more than 25 peer reviewed publications.

Dr. Duan began her career as a Senior Research Fellow at the National Cancer Institute where she studied tumor suppressor genes. She received her B.Sc. in Pharmacy from National Taiwan University and her Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco and worked as a postdoctoral fellow at the Howard Hughes Medical Research Institute at the University of California, San Francisco, on growth factors and their application in cardiovascular diseases.

Alan Rudolph, President and CEO of Adlyfe, said, "We are delighted that Roxanne has joined Adlyfe in this important new role. Her experience brings a critical skill set to our rapidly growing diagnostic product development activities. Her experience in protein biochemistry and development of protein based assays be instrumental to our efforts to develop diagnostic assays for neurodegenerative diseases such
'/>"/>

SOURCE Adlyfe
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Clintons new problem - Is the outgoing American president suffering from skin cancer?
2. Past President Narayanans Condition Still Critical
3. President and Founder of National Obesity Forum Resigns
4. President Bush Urges Citizens to Invest In Health Savings Account (HSAs)
5. President Bush proposes HSAs scheme for the benefit of both the workers and the country
6. President’s verdict: no need to panic over bird fl
7. Delhi Hospitals On Standby For President Bush
8. Former IMO President Shows Interest In Winning General Election
9. Chicken Dishes Were Off The Menu At Pakistan Presidents House
10. Man Appeals to President to Save His Ailing Son
11. President Kalam Meets Striking Medicos However Stir to Continue
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 52397 1Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 52397 2Biomodels Expands Efforts in Cancer Supportive Care Pulmonary Fibrosis 3B Preclinical Research Organization Names Dr Stephen T Sonis as Partner 13146 1Biomodels Expands Efforts in Cancer Supportive Care Pulmonary Fibrosis 3B Preclinical Research Organization Names Dr Stephen T Sonis as Partner 13146 2Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 1Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 2